Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease with Severely Elevated Serum Triglycerides

Nonalcoholic fatty liver disease accompanied by severely elevated serum triglycerides — for example, levels exceeding 500 mg/dL — defines a specific high-risk presentation of MASLD that calls for a targeted, evidence-based approach.

Clinical Scenario

This protocol applies to patients with nonalcoholic fatty liver disease who have severely elevated serum triglycerides (eg, >500 mg/dL). At this threshold, the clinical priority extends beyond liver disease management to include reduction of pancreatitis risk.

Treatment Approach (partial)

Management begins with lifestyle changes alongside targeted lipid-lowering therapy. When triglycerides are severely elevated, specific agents — or a combination of agents — are indicated to address the elevated risk. The full sequence of options and the complete clinical algorithm are in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/HEP.0000000000000323

Hypertriglyceridemia can be managed through lifestyle changes and supplementation with omega-3 fatty acids, icosapent ethyl, or fibrates.
In patients with NAFLD and severely elevated triglycerides levels (eg, >500 mg/dL), fibrates, or a combination of fibrates with prescription grade omega-3 fatty acids or icosapent ethyl, should be used to reduce the risk of pancreatitis.

View source ↗